Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast Cancer

Video

In Partnership With:

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Christopher A. Klebanoff, MD, medical oncologist, head, Breast Immunotherapy Section, Memorial Sloan Kettering Cancer Center, discusses using biosimilars to reduce financial toxicity in breast cancer.

Biosimilars will greatly reduce the financial toxicity of many therapeutics available to patients with breast cancer, most notably patients with HER2-positive disease, explains Klebanoff. In addition to the cancer treatments, there are other biologics, specifically granulocyte-colony stimulating factor, that are commonly used in the adjuvant setting as a neutrophil immune booster that can also cause financial toxicity, says Klebanoff.

With biosimilars, the registration data demonstrate equivalence similar to conventional generics in terms of efficacy and reduced financial cost, making them a positive option for patients and providers, concludes Klebenoff.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD